Navigation Links
Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announces that positive interim data from an ongoing phase II trial of ZIO-201 (isophosphoramide mustard - IPM) to treat advanced sarcoma patients was presented at the European Society of Medical Oncology (ESMO) meeting held July 5-8, 2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/II Study of IPM (ZIO-201) In Advanced Sarcoma," was presented by Rashmi Chugh, MD, a Principal Investigator from the University of Michigan, Ann Arbor, Michigan.

The trial has now enrolled 39 patients and this presentation reports on the first 10 evaluable patients. Of these 10 heavily pretreated patients (median 4 prior regimens), 1 has a partial response (21 weeks and ongoing) and 4 have stable disease. Of these 5 patients, 2 had progressed through prior ifosfamide (IFOS) treatment. ZIO-201 was shown to be well tolerated at the phase II dose with no significant bone marrow suppression, alopecia (hair loss) or neurotoxicity reported. Based on this encouraging data, enrollment has been expanded to include additional patients.

"Ifosfamide is one of the few effective standard therapies available for most sarcomas," commented Dr. Chugh. "Having a novel drug that could offer the benefits of high-dose ifosfamide without the debilitating side effects, particularly the bone marrow suppression and neurotoxicity, would be of great benefit in the treatment of this disease. We are enthusiastic about these early results and we look forward to further elucidating the overall impact of ZIO-201 in this setting."

The Company expects to report more complete data at upcoming medical meetings, including the 14th European Cancer Conference (ECCO) taking place in Barcelona from September 23-27, 2007.

About ZIO-201

ZIO-201, the active moiety of IFOS, is a bi-functional alkylator that causes irreparable inter-strand DNA cross- linking resulting in cell death. ZIO-201 is equal to or more active than IFOS in diverse cancer models. Unlike IFOS, which is a pro-drug, ZIO-201 is directly active against cancer cells. Also, unlike IFOS, ZIO-201 is not metabolized to acrolein or chloroacetaldehyde which cause bladder or central nervous system toxicities. ZIO-201 continues in a phase I trial in diverse cancers exploring maximum tolerated dose at alternate schedules. A phase II trial in advanced sarcoma continues to enroll patients. Trials in lymphoma and pediatric cancers are in the advanced planning stage. An oral form of ZIO-201 is in advanced preclinical development.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.

ZIOP-G

Contact

ZIOPHARM Oncology, Inc.
Investors
Suzanne McKenna, 646-214-0703
smckenna@ziopharm.com
or
Media
Tina Posterli, 917-322-2565
tposterli@rxir.com


'"/>




Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
11. Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ ... full service medical device development firm, announced today that ... Toronto -based medical device industrial design and ... medtech companies throughout North America ... medical device talent spanning the design, engineering, regulatory, and ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
(Date:3/28/2017)... 2017 RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... Patent Office (JPO) for the composition of matter ... for the treatment or prevention of fibrotic disorders, ... proliferative retinopathy (Japanese Patent #: 6060071).  This patent ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... City ... holidays (IBT World Travel Trends Report). As travelers visit both urban destinations, they ... temperatures, and prolonged sun exposure. In response, the outdoor industry has blurred the ...
(Date:3/28/2017)... ... , ... Alert Sentry Group LLC., a leader in the Personal Emergency Response ... and the iSAFE Plus. These iSAFE products are the most affordable and most advanced ... iSAFE Plus offer direct GPS Location and two-way calling with the push of a ...
(Date:3/28/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) is pleased ... new executive director. Mr. Still was selected through a careful months-long search by the ... is known to our members, has been a part of building the RBMA since ...
(Date:3/28/2017)... Vilnius, Lithuania (PRWEB) , ... March 28, 2017 ... ... identification technologies, today announced the release of two biometric time and attendance tracking ... Bio Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition ...
(Date:3/28/2017)... ... 28, 2017 , ... The Executives, Staff & Clients of MGE: Management Experts ... for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. ... ranks at number 14 internationally in literacy. Statistically, a direct relation can be a ...
Breaking Medicine News(10 mins):